US FDA staff flags risk of low blood sugar for Novo Nordisk’s weekly insulin

Novo Nordisk

US FDA staff flags risk of low blood sugar for Novo Nordisk’s weekly insulin

May 22 (Reuters) – The U.S. Food and Drug Administration’s (FDA) staff on Wednesday pointed to “notable imbalance” in incidence of low blood sugar in patients with type 1 diabetes treated with Danish drugmaker Novo Nordisk’s (NOVOb.CO) long-acting weekly insulin.
 
A panel of independent FDA advisers will meet on Friday to review and discuss the safety and effectiveness of Novo’s insulin, icodec — an under-the-skin injection.
 
Source: Reuters
/by
You might also like
WegovyNovo Nordisk shares down after analysis finds Lilly drug leads to better weight loss
FDA2SeventyBio’s partner pauses cancer therapy study after patient death
Novo NordiskNovo Nordisk braces for generic challenge to Ozempic, Wegovy in China
FDAReutersFDA classifies recall of Getinge’s heart devices as most serious
Eye examApellis eye injection treatment flagged for safety issues
As Novo and Lilly focus on a few big markets, Sanofi seeks global reach for diabetes GLP-1 drug
GSKFDA approves GSK’s momelotinib for myelofibrosis patients with anemia
FDAUS FDA staff flags concerns on MDMA-assisted PTSD treatment